Type I Insulin-Like Growth Factor Receptor Signaling in Hematological Malignancies.

Deeksha Vishwamitra,Suraj Konnath George,Ping Shi,Ahmed O. Kaseb,Hesham M. Amin
DOI: https://doi.org/10.18632/oncotarget.12123
2016-01-01
Oncotarget
Abstract:The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss current understanding of the role of IGF-IR signaling in cancer with a focus on the hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.
What problem does this paper attempt to address?